Clinical trialNCT05996627RecruitingPhase 2Interventional

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

SponsorFred Hutchinson Cancer CenterEnrollment82Chronic Graft Versus Host Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Stephanie Lee, MD, MPH
Fred Hutch/University of Washington Cancer Consortium
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Sunmin Park, MD
Not, yet, recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Joseph Pidala, MD, PhD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Corey Cutler, MD, MPH
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Doris Ponce, MD
Recruiting
Fred Hutch/university of Washington Cancer Consortium
Seattle, Washington, United States
Stephanie Lee, MD, MPH
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Belumosudil →Placebo Administration

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Dec 2023
Primary completion: 30 Apr 2028
Completion: 30 Nov 2028
Last update posted: 21 Aug 2026
Registered enrollment: 82
Registry id: NCT05996627

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.